Miro Sciences Ltd (NSB.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.054 (+0.00%) as of
Key statistics
- Market cap
- 21.04M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0410 – 0.1800
- Beta
- 1.23
- Revenue (TTM)
- 402.66k
- Profit margin
- 0.00%
- Analyst target
- A$0.43
- Volume
- 209.53k
About Miro Sciences Ltd
Miro Sciences Ltd engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. Miro Sciences Ltd was formerly known NeuroScientific Biopharmaceuticals Limited and change its name to Miro Sciences Ltd in October 2026. The company was incorporated in 2002 and is based in Nedlands, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Nedlands, WA, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.